Dernières nouvelles pour Senseonics Holdings (AMEX:SENS) Stock

SENSEONICS HOLDINGS INC

Senseonics Holdings

Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.

Senseonics Holdings Inc

SENSO

SENSHU ELECTRIC CO LTD by SENSHU ELECTRIC CO LTD.

SENSHU IKEDA HLDGS INC by Senshu Ikeda Holdings Inc.

SENSIO TECHNOLOGIES INC by SENSIO Technologies Inc.

SENSYNE HEALTH LTD by Sensyne Health Ltd.

SENSEN NETWORKS LTD by SenSen Networks Limited

SenSen Networks Ltd

SENSASURE TECHNOLGIES INC by SensaSure Technologies, Inc.

Sensasure Technologies Inc

Sensata Technologies Holding plc Ordinary Shares

Sensata Technologies Holding PLC

SENSE TECHS INC ORD by Sense Technologies, Inc.

Sense Technologies Inc

SENSETIME GRP INC CL B by SENSETIME GROUP INC.

SenseTime Group Inc

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics Inc

SENSIBLE MEATS INC by SENSIBLE MEATS INC.

Sensible Meats Inc

Sensient Technologies Corporation Common Stock

Sensient Technologies Corp

Senstar Technologies Corporation - Common Shares

Senstar Technologies Corp

Sensus Healthcare Inc

News

IONQ

Texas Legislature Passes IonQ-Backed Quantum Initiative, Paving The Way For Statewide Leadership In Quantum Innovation

Rep. Thomas Massie (R-Ky.) has warned that the passage of President Donald Trump's &#8216;One Big Beautiful Bill&#8217; could tank the U.S. credit rating to BBB status, a level that historically signals financial distress.
What Happened: In an X post, Massie quipped, "BBB = our credit rating if this bill becomes law," using the hashtag #sassywithmassie to underscore his skepticism.
The legislation, a sweeping tax and spending package, is set for a Senate vote, with the Congressional Budget Office projecting an increase in the national debt over the next decade.
Massie's critique comes amid growing concerns over fiscal responsibility, following a rare downgrade of U.S. debt to<a href="https://www.benzinga.com/news/econ-s/25/05/45479078/moodys-downgrades-us-credit-rating-over-debt-deficit-concerns"> Aa1 by Moody's</a> on May 16, which cited rising deficits and inadequate spending cuts.
The One Big Beautiful Bill, championed by President Trump, includes tax cuts on Social Security income and tips, alongside Medicaid restrictions, but critics like Massie argue it fails to address core conservative priorities like deficit reduction or welfare reform for illegal immigrants.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">"BBB" = our credit rating if this bill becomes law<a href="https://twitter.com/hashtag/sassywithmassie?src=hash&amp;ref_src=twsrc%5Etfw">#sassywithmassie</a>
&mdash; Thomas Massie (@RepThomasMassie) <a href="https://twitter.com/RepThomasMassie/status/1939128423093329955?ref_src=twsrc%5Etfw">June 29, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to a <a href="https://www.colorado.edu/today/2025/05/21/what-us-credit-downgrade-means-economy-and-your-wallet">report</a> by the University of Colorado, Nathalie Moyen, a finance professor at the Leeds School of Business, highlights that a credit downgrade could mean higher borrowing costs. Interest rates on loans, mortgages, and credit cards might rise as investors demand more return to offset perceived risk, directly hitting household budgets.
&#8220;Meanwhile, the U.S. government now faces higher interest payments on its own debt. Eventually, that pressure will likely lead to higher taxes or cuts in government spending, both of which will be felt by everyday Americans,&#8221; said Moyen.
Additionally, David Beahm, President &amp; CEO of Blanchard and Company, explained <a href="https://finance.yahoo.com/news/moody-us-credit-rating-downgrade-110454282.html">to</a> Yahoo Finance that the U.S. could be seen as a risky borrower after a downgrade, and &#8220;investors may demand higher interest rates in exchange for taking on what they see as greater risk in lending to the U.S.&#8221;
See Also: <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/46112471/ross-gerber-touts-an-idea-to-cut-deficit-by-trillions-of-dollars-let-the-tax-cuts-expire-and-full-salt-come-back">Ross Gerber Touts An Idea To Cut Deficit By Trillions Of Dollars: &#8216;Let The Tax Cuts Expire And Full SALT Come Back&#8217;</a>
Why It Matters: The Congressional Budget Office's estimates on the distributional impacts of the One Big Beautiful Bill Act revealed that tax adjustments, including the extension of 2017 tax act provisions, would<a href="https://www.benzinga.com/markets/equities/25/05/45536595/big-beautiful-bill-will-explode-the-deficit-and-make-the-rich-richer-congressional-budget-office-estimates-4-income-fall-for-lowest-decile-of-americans-by-2033"> drive a $3.8 trillion rise in the federal deficit</a>. 
Additionally, the CBO report highlights a $698 billion cut in federal subsidies due to modifications in the Medicaid program, alongside a $267 billion reduction in federal outlays for the Supplemental Nutrition Assistance Program (SNAP).
The report further noted, &#8220;Household resources would decrease by an amount equal to about 2 percent of income in the lowest decile (tenth) of the income distribution in 2027 and 4 percent in 2033, mainly as a result of losses of in-kind transfers, such as Medicaid and SNAP.&#8221;
Conversely, household resources would grow by 4% for those in the highest decile in 2027 and 2% in 2033, primarily due to &#8220;reductions in the taxes they owe.&#8221;
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were trading higher in premarket on Monday. The SPY was up 0.45% at $617.65, while the QQQ advanced 0.70% to $551.95, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
After hitting a fresh record on Friday, the futures of the S&amp;P 500, Nasdaq 100, and Dow Jones indices were trading higher on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46068345/blackrock-bets-big-on-defense-companies-amid-escalating-geopolitical-tensions-palantir-lockheed-martin-northrop-grumman-among-stocks-in-focus" target="_blank" rel="noreferrer noopener">BlackRock Bets Big On Defense Companies Amid Escalating Geopolitical Tensions: Palantir, Lockheed Martin, Northrop Grumman Among Stocks In Focus</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. Image Credit: CLIFFORD OTO/THE STOCKTON RECORD / USA TODAY NETWORK via Imagn Images

US Credit Rating Would Fall If Trump's Big Beautiful Bill Is Approved, Says Thomas Massie: Here's What It Means For Americans

<ul>
<li>Univation's new C3 AI–powered predictive maintenance solution for the petrochemical industry delivers enhanced operational efficiency, reduced maintenance expenses, and improved asset availability — leveraging insights from Dow Inc.'s successful implementation across its manufacturing facilities.</li>
<li>This collaboration builds off Dow's success with C3 AI Reliability, currently scaling across Dow's global steam cracking furnace fleet and other critical assets.</li>
</ul>

C3 AI And Univation Collaborate To Maximize Uptime And Cut Maintenance Costs For Petrochemical Manufacturers Worldwide

<ul>
<li>PanTracer Tissue evaluates over 500 cancer-related genes and aligns with clinical guidelines, covering key biomarkers recommended for therapy selection and additional genomic insights for clinical trial enrollment. Results may be delivered in as little as 8 days, enabling physicians to rapidly initiate treatment strategies. Minimal specimen requirements make it suitable for a wide range of tumor types and practice settings. The assay builds on the company's tissue-based CGP platform, previously known as NeoComprehensive Solid Tumor.</li>
<li>The addition of PanTracer Tissue + HRD offers enhanced tumor profiling by incorporating homologous recombination deficiency analysis into a single, guideline-aligned test for ovarian cancer. The PanTracer Tissue + HRD offering includes BRCA mutation status and a genomic instability score—critical biomarkers that can help guide the use of PARP inhibitors and other therapies targeting DNA repair pathways. The combined approach streamlines ordering and can shorten time to actionable results by capturing a broader range of clinically relevant genomic alterations, gene fusions, and DNA repair deficiencies.</li>
</ul>

Health Care

General

NeoGenomics Announced The Launch Of PanTracer Tissue, A Next-generation Solid Tumor Profiling Assay, Including The Option To Add Testing For Homologous Recombination Deficiency

Nexstar Media Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXST#NASDAQ">NXST</a>) (the "Company") announced today that its wholly owned subsidiary, Nexstar Media Inc. ("Nexstar"), and Mission Broadcasting, Inc. ("Mission"), a variable interest entity of the Company, successfully completed refinancings of their revolving credit facilities, Term Loan A and Term Loan B in full. The refinancing extends maturities, provides expanded capacity under Nexstar's revolver, reduces interest rate margin and further strengthens the Company's capital structure and financial flexibility.
The new credit facilities include:
<ul>
<li>New $750 million Nexstar Revolving Credit Facility due 2030</li>
<li>New $75 million Mission Revolving Credit Facility due 2030</li>
<li>New $1,905 million Nexstar Term Loan A due 2030</li>
<li>New $1,300 million Nexstar Term Loan B due 2032</li>
</ul>
The revolving credit facilities and Term Loan A bear interest at the Secured Overnight Financing Rate (SOFR) plus 150 basis points per annum (subject to a pricing grid), representing a 10 basis point credit spread reduction compared to the rate on the prior credit facilities. The revolving credit facilities and Term Loan A priced with an upfront fee of 0.125% or 0.25% for rolled or new commitments. The Term Loan B bears interest at SOFR plus 250 basis points per annum, representing an 11 basis point credit spread reduction for 1-month SOFR compared to the rate on the prior Term Loan B. The Term Loan B priced with an original issue discount of 1.00%.
Together with cash on hand, the net proceeds of the new credit facilities refinanced Nexstar's $550 million revolving credit facility due 2027, Mission's $75 million revolving credit facility due 2027, Nexstar's $2,091 million Term Loan A due 2027 and Nexstar's $1,358 million Term Loan B due 2026 along with transaction fees and expenses.

NXST

Nexstar Media Subsidiaries Complete Refinancings Of Revolving Credit Facilities, Term Loan A And Term Loan B In Full; Refinancing Extends Revolving Credit Facility And Term Loan Maturities And Reduces Interest Rate Margin

Biotech

INDV

Indivior Will Be Added As A Member Of The US Small-cap Russell 2000 Index, Effective After The Us Market Opens Today As Part Of The 2025 Russell Indexes Reconstitution.

Modine Unveils DSU Destratification Fan To Deliver Quiet, Energy-Efficient Airflow For Industrial And Commercial Facilities

<ul>
<li>Re-enters the mine on June 10th, consistent with previously provided timeline</li>
<li>Re-establishes ventilation, conducts a full inspection of the mine, restores hydraulic pressure along the longwall face, and confirms that key longwall components are in good condition</li>
<li>Decides to temporarily reseal the affected area of the mine on June 26th due to elevated carbon monoxide levels</li>
<li>Engages regulatory officials on a plan that is expected to facilitate the repositioning and restart of the longwall system within the next four months</li>
<li>Reiterates 2025 coking coal sales volume guidance for metallurgical segment despite delayed restart</li>
<li>Expects Leer South-related insurance recoveries in excess of $100 million&nbsp;</li>
</ul>

Core Natural Resources Temporarily Reseals Affected Leer South Mine Area Due To Carbon Monoxide Spike; Restart Targeted Within Four Months

<ul>
<li>Study highlights high mortality despite standard of care and provides critical data to optimize design for upcoming proof-of-concept trial for epetraborole</li>
<li>Observational Study funded by the National Institutes of Health</li>
</ul>

ANTX

AN2 Therapeutics Completed Its 200-patient Observational Study In Acute Melioidosis. The Study Evaluated Patients Receiving The Current Standard Of Care: IV Meropenem Or Ceftazidime

RP-A701 is a first-in-class gene therapy for the treatment of BAG3-associated dilated cardiomyopathy
BAG3-associated dilated cardiomyopathy is a rare, inherited heart condition caused by mutations in the BAG3 gene, leading to early-onset, progressive heart failure due to impaired cardiac function, high morbidity, and premature mortality
Rocket plans to conduct a Phase 1 trial in the U.S. and is working towards the first patient treatment
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Frocketpharma.com%2F&amp;esheet=54283361&amp;newsitemid=20250630555497&amp;lan=en-US&amp;anchor=Rocket+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=6a3f55fb2d18a5941dd91131e5832f93">Rocket Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the Company's Investigational New Drug (IND) application for RP-A701, an AAVrh.74-based gene therapy candidate for the treatment of BAG3-associated Dilated Cardiomyopathy (BAG3-DCM), a severe form of heart failure characterized by progressive ventricular enlargement and impaired systolic function.

RCKT

Rocket Pharma Receives FDA Clearance For IND Application For RP-A701, Aavrh.74-Based Gene Therapy Candidate For Treatment Of BAG3-Associated Dilated Cardiomyopathy

LTRX

Lantronix Reaches Cooperation Agreement With Chain Of Lakes Investment Group, Appoints Jim Auker To Board

HC Wainwright &amp; Co. analyst Andrew Fein assumes Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) with a Buy rating and announces Price Target of $23.

Price Target

Initiation

Analyst Ratings

CADL

HC Wainwright & Co. Assumes Candel Therapeutics at Buy, Announces Price Target of $23

<ul>
<li>Complete Response Letter (CRL) cited deficiencies previously identified at a third-party manufacturing vendor unrelated to Oxylanthanum Carbonate (OLC).</li>
<li>No other concerns stated, including pre-clinical, clinical, or safety data.</li>
<li>The Company identified a second manufacturing vendor that has already produced OLC drug product, which could also be used to support the resolution of the Clinical Manufacturing and Controls (CMC) issues identified in the CRL.</li>
<li>The Company plans to immediately request a Type A meeting with the FDA to align on next steps.</li>
<li>Unicycive currently has an unaudited cash balance of approximately $20.7 million, with cash runway currently expected into the second half of 2026</li>
</ul>

UNCY

The FDA Issues Complete Response Letter For Unicycive Therapeutics' New Drug Application For Oxylanthanum Carbonate To Treat Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis

Walker & Dunlop Secures $170M To Refinance Post District, A Class A, Mixed-Use Complex Containing 580 Residential Units In Downtown Salt Lake City, Utah

COIN

WBUY

Webuy Global Partners With Coinbase Commerce To Launch Stablecoin Payment Option For Global Travel And E-Commerce Offerings

NLSP

NLS Pharma Completes Second And Final $1M Closing Of $3M Equity Financing Of Preferred Shares And Warrants From March 2025

President Donald Trump escalated his war of words with Federal Reserve Chair Jerome Powell on Sunday, accusing him of keeping interest rates &#8220;artificially high&#8221; and insisting the benchmark should drop to "1% or 2%&#8221;, half of what it is now.
What Happened: Appearing on Fox News' "Sunday Morning Futures," Trump <a href="https://www.foxbusiness.com/politics/trump-blasts-powell-says-any-replacement-would-better-refinancing-9t-debt">called</a> Powell a "stupid person" and &#8220;a bad person,&#8221; claiming the Fed chief's policies force the government to refinance roughly $9 trillion in debt at punitive costs.
&#8220;We have a bad Fed chairman," he said. "But&#8230; the numbers are so good it doesn't even matter that he keeps the rates artificially high.&#8221;
The President's broadside followed months of threats to fire Powell, warnings that rattled bond markets earlier this year. After legal advisers cautioned that dismissing the chair could <a href="https://www.benzinga.com/25/05/45579414/supreme-court-says-trump-cant-fire-jerome-powellthe-fed-a-uniquely-structured-quasi-private-entity">violate the Fed's independence</a>, Trump shifted to pledging a successor who will slash borrowing costs. "I know within <a href="https://www.benzinga.com/news/25/06/46115346/trump-powell-fed-chairman-odds-dollar">three or four people</a> who I'm going to pick," he told reporters last week at a NATO summit, labeling Powell "terrible," according to Reuters.
See also: <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/46163659/senate-republicans-propose-313-billion-cut-in-medicaid-spending-in-trumps-big-beautiful-bill">Senate Republicans Propose $313 Billion Cut In Medicaid Spending In Trump&#8217;s &#8216;Big, Beautiful Bill&#8217;</a>
Why It Matters: Treasury Secretary Scott Bessent <a href="https://www.cnbc.com/2025/06/27/cnbc-transcript-us-treasury-secretary-scott-bessent-speaks-with-cnbcs-morgan-brennan-on-closing-bell-overtime-today.html">said</a> on CNBC that the administration could nominate a replacement as soon as October, raising the prospect of a &#8220;shadow Fed&#8221; months before Powell's term ends in May 2026. Trump confirmed he would not appoint anyone "who doesn't want to cut rates," and singled out former Fed governor Kevin Warsh as "very talented," though he stopped short of endorsing him, states Reuters.
The Fed's target range stands at <a href="https://www.benzinga.com/markets/economic-data/25/06/46087650/feds-schmid-says-wait-and-see-approach-right-for-rate-policy-as-tariff-fallout-still-unclear">4.25%–4.5%</a> after aggressive 2024 hikes. Policymakers signaled modest easing later this year but argue larger cuts risk reigniting tariff-driven inflation.
Critics warn that overt <a href="https://www.benzinga.com/news/25/04/45027556/after-powell-trumps-fed-nominee-will-be-a-loyal-soldier-says-peter-schiff-willing-to-sacrifice-the-dollar-create-inflation-as-needed">political pressure</a> could erode the central bank's credibility and unsettle global markets. A report from the Peterson Institute suggests that undermining the Fed&#8217;s independence could lead to a&nbsp;<a href="https://apnews.com/article/trump-inflation-tariffs-taxes-immigration-federal-reserve-a18de763fcc01557258c7f33cab375ed" target="_blank" rel="noopener">persistent</a>&nbsp;2 percentage point annual increase in inflation, <a href="https://apnews.com/article/trump-inflation-tariffs-taxes-immigration-federal-reserve-a18de763fcc01557258c7f33cab375ed">according</a> to an AP report.
Read next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/46163670/trumps-bills-over-bonds-strategy-can-spell-doom-for-the-dollar-warns-craig-shapiro-got-gold-bitcoin">Trump&#8217;s &#8216;Bills Over Bonds&#8217; Strategy Can Spell Doom For The Dollar, Warns Craig Shapiro: &#8216;Got Gold, Bitcoin?&#8217;</a></li>
</ul>
Image via Shutterstock

Politics

Economics

Federal Reserve

Markets

Donald Trump Calls Fed Chair Jerome Powell A 'Bad Person' Who Keeps Rates 'Artificially High,' Says Benchmark Should Drop By Half

HC Wainwright &amp; Co. analyst Joseph Pantginis initiates coverage on Edgewise Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) with a Buy rating and announces Price Target of $42.

EWTX

HC Wainwright & Co. Initiates Coverage On Edgewise Therapeutics with Buy Rating, Announces Price Target of $42

<ul>
<li>In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plus darolutamide in men with metastatic castration resistant prostate cancer ("mCRPC"). the six-month radiographic progression free survival ("rPFS") rate was 66%.</li>
<li>In a Phase 2 clinical trial of gedatolisib plus trastuzumab-pkrb as 3L+ therapy in patients with HER2+ metastatic breast cancer ("mBC"), the objective response rate ("ORR") was 43%.</li>
<li>No patients discontinued gedatolisib due to a treatment-related adverse event ("AE") in either clinical trial</li>
</ul>

CELC

Celcuity Announced Preliminary Clinical Data For Gedatolisib In Two Early-phase Clinical Trials

HCAI

Huachen AI Parking Enters Into Non-Binding Cooperative Agreement With Hangzhou Qianhui To Enhance Two-Wheeled E-Charging Infrastructure

Press Releases

Senseonics Holdings, Inc. to Participate in the TD Cowen 45th Annual Health Care Conference

Eversense 365 and SweetSpot Integrate Software to Optimize Diabetes Care

Earnings

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

Sequel Med Tech and Senseonics Integrate Technologies to Create First Automated Insulin Delivery (AID) System with One-Year Continuous Glucose Monitor (CGM)

Senseonics Holdings, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for May 8, 2025 at 4:30 P.M. Eastern Time

Senseonics Holdings, Inc. Reports First Quarter Financial Results

Senseonics Announces Commencement of $50 Million Public Offering of Common Stock and Concurrent Private Placement

IPOs

Senseonics Announces Pricing of $50 Million Public Offering of Common Stock and Concurrent Private Placement

Financing

Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters' Option to Purchase Additional Shares, and Closing of Private Placement

Senseonics Holdings, Inc. to Host In-Person and Virtual Analyst Event at ADA 2025: Eversense® 365 Continuous Glucose Monitoring System for People with Diabetes

SENS

AngioDynamics

Axogen

Beta Bionics

Butterfly Network, Inc. Class A Common Stock

Butterfly Network

BioSig Technologies

BrainsWay Ltd. - American Depositary Shares

BrainsWay

CeriBell

ClearPoint Neuro

Delcath Systems

Alpha Tau Medical

iRadimed

Kestra Medical Technologies, Ltd. - Common Stock

Kestra Medical Techs

NeuroPace

Orthofix Medical

Outset Medical

Sight Sciences

SI-BONE

Semler Scientific

SANUWAVE Health

Surmodics

Neuronetics

Tactile Systems Technology, Inc. - Common Stock

Tactile Systems Tech

Treace Medical Concepts, Inc. - Common Stock

Comments

Senseonics Holdings

Actualités

Dernières nouvelles pour Senseonics Holdings (AMEX:SENS) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL